Notices of Intent to Revise and Pharmacopeial Forum-Related Notices

<64> Probiotic Tests Notice of Intent to Revise (posted 30-Jun-2023)
<90> Fetal Bovine Serum Quality Attributes and Functionality (posted 05–Feb–2021)
<411> Folic Acid Assay and Folic Acid Tablets (posted 22–Apr–2022)
<621> Chromatography Notice of Intent to Revise (posted 06-Jan-2023)
<621>Chromatography Notice of Intent to Revise (posted 25-Aug-2023)
<660> Container-Glass (posted 27-Jan-2023)
<661.1> Plastic Materials of Construction Notice of Intent to Revise (posted 18–Dec–2020)
<661.2> Plastic Packaging Systems for Pharmaceutical Use Notice of Intent to Revise (posted 16-Dec-2022)
<665> Plastic Components and Systems Used to Manufacture Pharmaceutical Drug Products and Biopharmaceutical Drug Substances and Products Notice of Intent to Revise (posted 25–Feb–2022)
<795> Pharmaceutical Compounding—Nonsterile Preparations (posted 01–Sep–2021)
<797> Pharmaceutical Compounding— Sterile Preparations (posted 01–Sep–2021)
<1079.2> Mean Kinetic Temperature in the Evaluation of Temperature Excursions During Storage and Transportation of Drug Products (posted 27-Jan-2023)
Acyclovir Notice of Intent to Revise (posted 25–Feb–2022)
Acyclovir Notice of Intent to Revise (posted 16-Dec-2022)
Albuterol Inhalation Solution Notice of Intent to Revise (posted 16–Apr–2021)
Albuterol Inhalation Solution Notice of Intent to Revise (posted 29-Sep-2023)
Amantadine Hydrochloride Notice of Intent to Revise (posted 27–May–2020)
Aminocaproic Acid Oral Solution Notice of Intent to Revise (posted 31–Jul–2020)
Aprepitant Capsules, Galantamine Tablets, Praziquantel Tablets, and <1092> The Dissolution Procedure: Development and Validation Notice of Intent to Revise (posted 28–Aug–2020)
Azeotropic Isopropyl Alcohol Notice of Intent to Revise (posted 30–Apr–2021)
Bacillus coagulans (posted 28-Apr-2023)
Baclofen Injection Notice of Intent to Revise (posted 30–Apr–2021)
Benztropine Mesylate Notice of Intent to Revise (posted 28–Dec–2020)
Benztropine Mesylate Notice of Intent to Revise (posted 30–Apr–2021)
Bicalutamide Tablets Notice of Intent to Revise (posted 16-Dec-2022)
Bifidobacterium bifidium Notice of Intenet to Revise (posted 27–Aug–2021)
Bifidobacterium longum subsp. longum Notice of Intent to Revise (posted 27–Aug–2021)
Bupropion Hydrochloride Notice of Intent to Revise (posted 19–Feb–2021)
Changes to USP's Description and Solubility Reference Table (posted 30-Sep-2022)
Carbomer 934, Carbomer 934P, Carbomer 941, and Carbomer 1342 Notice of Intent to Revise (posted 18-Nov-2022)
Castor Oil Notice of Intent to Revise (posted 31–Jul–2020)
Chemical Information Updates (posted 28-Apr-2023)
Codeine Phosphate Notice of Intent to Revise (posted 26–Mar–2021)
Clonidine Transdermal System Notice of Intent to Revise (posted 27–Mar–2020)
Clonidine Transdermal Systems: Removal of the Test for Organic Impurities (posted 24-Feb-2023)
Copovidone Notice of Intent to Revise (posted 30–Apr–2021)
Cranberry Fruit Juice Dry Extract Notice of Intent to Revise (posted 30–Dec–2021)
Deferred Proposal: General Notices and Requirements, 5.60.40 Impurities that are Unusually Toxic and/or Mutagenic (posted 30–Sep–2020)
Dextran 40 Notice of Intent to Revise (posted 30–Jul–2021)
Dextran 70 Notice of Intent to Revise (posted 30–Jul–2021)
Dextrose Injection Notice of Intent to Revise (posted 15–Oct–2021)
Dextrose Injection Notice of Intent to Revise (posted 25–Feb–2022)
Diphenhydramine Hydrochloride Oral Powder Notice of Intent to Revise (posted 25–Sep–2020)
Dutasteride and Tamsulosin Hydrochloride Tablets Notice of Intent to Revise (posted 28-Jul-2023)
Erythromycin Ethylsuccinate for Oral Suspension (posted 27-Jan-2023)
Fondaparinux Sodium Notice of Intent to Revise (posted 30–Dec–2021)
Fosamprenavir Calcium Notice of Intent to Revise (posted 18-Nov-2022)
Fosfomycin Tromethamine (posted 05-Oct-2022)
Fosfomycin Tromethamine (posted 28-Apr-2023)
Gemfibrozil Tablets Notice of Intent to Revise (posted 28–Aug–2020)
General Chapters Affected by Omission to <1118> Monitoring Devices- Time, Temperature, and Humidity (posted 18-Apr-2023)
General Chapters Affected by Revision to <1724> Semisolid Drug Products- Performance Tests (posted 28-Apr-2023)
General Chapters Affected by Revisions to <1912> Measurement of Yield Stress of Semisolids (posted 28-Apr-2023)
Glucagon Notice of Intent to Revise (posted 01–Oct–2021)
Gramicidin Notice of Intent to Revise (posted 21–Jan–2022)
Gramicidin Notice of Intent to Revise (posted 25-Aug-2023)
Ioxilan Notice of Intent to Revise (posted 09-Aug-2022)
Inhalation Product Monographs: Removal of Performance Tests (posted 25–Jun–2021)
Ipratropium Bromide Inhalation Solution (posted 28–May–2021)
Ipratropium Bromide (posted 28-Apr-2023)
Isopropyl Alcohol Notice of Intent to Revise (posted 30–Apr–2021)
Isotretinoin Capsules Notice of Intent to Revise (posted 27-May-2022)
Lactobacillus acidophilus Notice of Intent to Revise(posted 30-Jun-2023)
Lactobacillus reuteri Notice of Intent to Revise (posted 27–Aug–2021)
Lacotbacillus rhamnosus Notice of Intent to Revise (posted 27–Aug–2021)
Lactobacillus rhamnosus Notice of Intent to Revise (posted 20–Nov–2020)
Lauroyl Polyoxyglycerides Notice of Intent to Revise (posted 19–Feb–2021)
Levalbuterol Hydrochloride (posted 22–Apr–2022)
Levalbuterol Inhalation Solution (posted 22–Apr–2022)
Ligilactobacillus salivarus Notice of Intent to Revise (posted 30-Jun-2023)
Magaldrate Family of Monographs Notice of Intent to Revise (posted 28-Jul-2023)
Magnesium Family of Monographs Notice of Intent to Revise (posted 27–Aug–2021)
Magnesium Sulfate Notice of Intent to Revise (posted 30–Dec–2021)
Mesalamine Delayed-Release Tablets Notice of Intent to Revise (posted 30–Jul–2021)
Methscopolomine Bromide Tablets Notice of Intent to Revise (posted 28-Jul-2023)
Mitotane Notice of Intent to Revise (posted 21–Apr–2022)
Mitotane Tablets Notice of Intent to Revise (posted 21–Apr–2022)
Monographs Affected by Revision to <126> Somatropin Bioidentity Tests (posted 30-Sep-2022)
Monographs Affected by Revision to <616> Bulk Density of Powders (posted 28-Apr-2023)
Monographs Affected by Revision to <795> Pharmaceutical Compounding- Nonsterile Preparations (posted 01-Nov-2022)
Monographs Affected by Revision to <797> Pharmaceutical Compounding- Sterile Preparations (posted 01-Nov-2022)
Monographs with Postponed Content (posted 30–Jul–2021)
Naloxone Hydrochloride Notice of Intent to Revise (posted 30-Sep-2022)
Norgestimate Notice of Intent to Revise (posted 25-Aug-2023)
Orlistat Notices of Intent to Revise (posted 28–May–2021)
Orlistat Capsules Notice of Intent to Revise (posted 28–May–2021)
Phenelzine Sulfate Notice of Intent to Revise (posted 29-Apr-2022)
Phenoxybenzamine Notice of Intent to Revise (posted 16-Dec-2022)
Prazosin Hydrochloride Notice of Intent to Revise (posted 03–Jan–2022)
Proposal to Add Flexibility in the Selection of Suitable Packaging and Storage for Parenteral Drugs (posted 27-Jan-2023)
Pyrazinamide Notice of Intent to Revise (posted 19–Feb–2021)
Rotigotine Notice of Intent to Revise (posted 30–Jul–2021)
Sitagliptin Tablets Notice of Intent to Revise (posted 30-Jun-2023)
Sodium Bicarbonate (posted 03-Apr-2023)
Starch TS Notice of Intent to Revise (posted 25-Aug-2023)
Sucrose Notice of Intent to Revise (posted 31-Mar-2023)
Sucrose Notice of Intent to Revise (posted 26–Feb–2021; updated 02–Apr–2021; updated 18–Jun–2021)
Talc Notice of Intent to Revise (updated 18–Dec–2020)
Technetium Tc 99m Monographs: Removal of Biological Tests (posted 30–Jul–2021)
Tetracycline, Tetracycline Hydrochloride and Tetracycline Hydrochloride Capsules Notice of Intent to Revise (posted 18–Dec–2020)
Upcoming Changes to USP's Description and Relative Solubility Reference Table (posted 24-Jun-2022)
Vancomycin Injection Notice of Intent to Revise (posted 25–Mar–2022)
Zinc Family of Monographs Notice of Intent to Revise (posted 25-Aug-2023)
Zinc Sulfate Injection Notice of Intent to Revise (posted 28-Jul-2023)
Ziprasidone Hydrochloride Notice of Intent to Revise (posted 27-May-2022)